Ferric carboxymaltose

Generic Name: Ferric carboxymaltose

Brand Names: Injectafer

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: 9007-72-1

Unique Ingredient Identifier: 6897GXD6OE

Background: Ferric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.

Indication: Ferric carboxymaltose is an iron replacement product indicated for the treatment of iron deficiency anemia in patients ≥1 year of age who have an intolerance to, or unsatisfactory response from, oral iron therapy. It is also indicated in adult patients who have non-dialysis-dependent chronic kidney disease.

Associated Conditions: Iron Deficiency Anemia (IDA)

Associated Therapies: -

Clinical Trials

Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency

Phase 3

Conditions: Iron Deficiency Anemia

Interventions: Drug: Polyglucoferron
Drug: Ferric carboxymaltose
Drug: Ferrous Sulfate

First Posted Date: 2019-01-28

Last Posted Date: 2021-11-11

Lead Sponsor: Dr. Frank Behrens

Target Recruit Count: 407

Registration Number: NCT03817957

Locations: 🇩🇪
Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital of Goethe-University, Frankfurt, Hessia, Germany

Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation

Phase 3

Completed

Conditions: Iron-deficiency
Transplant-Related Disorder

Interventions: Drug: Ferric carboxymaltose
Drug: Sodium chloride

First Posted Date: 2018-12-07

Last Posted Date: 2024-08-27

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 148

Registration Number: NCT03769441

Locations: 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
🇳🇱
University Medical Center Utrecht, Utrecht, Netherlands

Effects of Ferinject® on Anemia and Transfusion Rates After Cardiac Surgery

Phase 4

Completed

Conditions: Anemia, Iron Deficiency

Interventions: Drug: Ferric carboxymaltose
Drug: Placebo

First Posted Date: 2018-11-30

Last Posted Date: 2021-10-11

Lead Sponsor: St Joseph University, Beirut, Lebanon

Target Recruit Count: 194

Registration Number: NCT03759964

Locations: 🇱🇧
Hotel Dieu de France Hospital, Beirut, Lebanon

Postoperative Replacement of Intraoperative Iron Losses

Phase 4

Conditions: Blood Loss Anemia

Interventions: Drug: Crystalloid
Drug: Ferric carboxymaltose

First Posted Date: 2018-09-21

Last Posted Date: 2022-04-08

Lead Sponsor: Kepler University Hospital

Target Recruit Count: 360

Registration Number: NCT03680456

Locations: 🇦🇹
Universitätsklinik für Anästhesie und Intensivmedizin, Linz, Austria

Intravenous Iron in Adults With Cystic Fibrosis

Phase 4

Completed

Conditions: Cystic Fibrosis
Iron-deficiency

Interventions: Drug: Ferric carboxymaltose

First Posted Date: 2018-08-15

Last Posted Date: 2022-09-07

Lead Sponsor: University of Oxford

Target Recruit Count: 20

Registration Number: NCT03632525

Locations: 🇬🇧
John Radcliffe Hospital, Oxford, United Kingdom

To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia

Phase 3

Completed

Conditions: Iron Deficiency Anemia

Interventions: Drug: Ferric carboxymaltose
Drug: Iron sucrose

First Posted Date: 2018-07-19

Last Posted Date: 2021-06-10

Lead Sponsor: Vifor (International) Inc.

Target Recruit Count: 371

Registration Number: NCT03591406

Locations: 🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China

Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery

Phase 4

Conditions: Aortic Aneurysm, Thoracic
Coronary Artery Disease
Aortic Valve Stenosis
Postoperative Complications
Mitral Valve Disease

Interventions: Other: Physiological saline
Drug: Ferric carboxymaltose

First Posted Date: 2018-06-29

Last Posted Date: 2021-04-20

Lead Sponsor: Turku University Hospital

Target Recruit Count: 210

Registration Number: NCT03574311

Locations: 🇫🇮
Turku University Hospital, Turku, Finland

Effect of Postoperative Ferric Carboxymaltose

Phase 4

Conditions: Postoperative Anemia
Total Knee Arthroplasty
Knee Osteoarthritis

Interventions: Drug: 0.9% Normal Saline
Drug: Ferric carboxymaltose

First Posted Date: 2018-06-19

Last Posted Date: 2018-06-19

Lead Sponsor: The Catholic University of Korea

Target Recruit Count: 80

Registration Number: NCT03561480

Effect of Preoperative Ferric Carboxymaltose After Simultaneous Bilateral Total Knee Arthroplasty

Phase 4

Conditions: Postoperative Anemia
Knee Osteoarthritis
Total Knee Arthroplasty

Interventions: Drug: 0.9% Normal Saline
Drug: Ferric carboxymaltose

First Posted Date: 2018-06-19

Last Posted Date: 2018-06-19

Lead Sponsor: The Catholic University of Korea

Target Recruit Count: 80

Registration Number: NCT03561506

Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA

Phase 3

Completed

Conditions: Iron Deficiency Anemia

Interventions: Drug: Ferrous Sulfate
Drug: Ferric carboxymaltose

First Posted Date: 2018-05-14

Last Posted Date: 2022-06-22

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 79

Registration Number: NCT03523117

Locations: 🇺🇸
ProHealth Research Center, Doral, Florida, United States
🇺🇸
Garden Medical Research, Inc., Miami, Florida, United States
🇺🇸
Miami Clinical Research, Miami, Florida, United States

and more 13 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy